By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Almost one year to the day after pulling a planned initial public offering, Seattle-based Atossa Genetics has refiled with US regulators to go public.

In a Form S-1 filed Feb. 13 with the US Securities and Exchange Commission Atossa said it seeks to sell 1 million shares of its common stock at a price of between $5 and $7 per share, raising up to a little more than $8 million.

The company plans to list on the Nasdaq Capital Market under ticker symbol "ATOS."

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Genome Research this week: mitochondrial and nuclear gene fusions in cancer, role of genomic imprinting in tissue-specific gene expression, and more.

Maria Freire from the Foundation for the NIH calls for "politically popular pledges of support" for the NIH to turn into support for increased funding for the agency.

A Thomson Reuters analysis indicates that the life sciences, rather than the tech sector, are increasingly driving global innovation.

The White House says ethical discussions about genome editing of the human germline are needed.